AR062038A1 - Neurotrofinas modificadas post-traduccionalmente - Google Patents

Neurotrofinas modificadas post-traduccionalmente

Info

Publication number
AR062038A1
AR062038A1 ARP070103275A ARP070103275A AR062038A1 AR 062038 A1 AR062038 A1 AR 062038A1 AR P070103275 A ARP070103275 A AR P070103275A AR P070103275 A ARP070103275 A AR P070103275A AR 062038 A1 AR062038 A1 AR 062038A1
Authority
AR
Argentina
Prior art keywords
retained
conserved
trp
residue selected
post
Prior art date
Application number
ARP070103275A
Other languages
English (en)
Inventor
Pehar Mariana
Cassina Patricia
M Alzari Pedro
Barbeito Luis
Original Assignee
Pasteur Institut
Inst De Investigaciones Biolog Clemente Estable I I B C E
Facultad De Medicina Universidad De La Republica
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst De Investigaciones Biolog Clemente Estable I I B C E, Facultad De Medicina Universidad De La Republica, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of AR062038A1 publication Critical patent/AR062038A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)

Abstract

Las neurotrofinas sufren modificaciones post-transduccionales y estas modificaciones post-transduccionales median la actividad pro-apoptótica y/o pro-neuritas de las neurotrofinas. Estas modificaciones post-transduccionales incluyen notablemente la nitración y la formación de dímeros de diferente conformación, así como también de oligómeros anormales, tales como tetrámeros y octámeros. Se proveen así agentes útiles para el tratamiento de las condiciones o enfermedades que involucran dolor crónico y/o pérdidas neuronales. Reivindicación 1: Un inductor y/o estimulador de la apoptosis neuronal motriz y/o del crecimiento de neuritas, el cual comprende: una neurotrofina modificada en una forma aislada, en donde por lo menos un residuo seleccionado de residuos Tyr y Trp comprende por lo menos un grupo nitrito, un fragmento conservado de dicha forma aislada de la neurotrofina modificada, en donde dicho fragmento conservado tiene retenido por lo menos un residuo seleccionado entre residuos Tyr y Trp, y donde dicho fragmento conservado tiene retenido por lo menos un grupo nitro en dicho al menos un residuo seleccionado entre residuos Tyr y Trp, y tiene retenida una capacidad de inducir y/o estimular la apoptosis neuronal motriz y/o el crecimiento de neuritas; o una variante conservada de dicha forma aislada de la neurotrofina modificada o de dicho fragmento conservado, en donde dicha variante conservada deriva de dicha neurotrofina modificada o de dicho fragmento conservado por la substitución y/o deleción y/o agregado de al menos un aminoácido, pero tiene retenido por lo menos un residuo seleccionado entre residuos Tyr y Trp, y donde dicha variante conservada tiene retenido por lo menos un grupo nitro en dicho al menos un residuo seleccionado entre residuos Tyr y Trp, y tiene retenida una capacidad de inducir y/o estimular la apoptosis neuronal motriz y/o el crecimiento de neuritas.
ARP070103275A 2006-07-24 2007-07-24 Neurotrofinas modificadas post-traduccionalmente AR062038A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291195A EP1882697B1 (en) 2006-07-24 2006-07-24 Antibodies, antibody fragments and scFv binding to post-translationally modified neurotrophins

Publications (1)

Publication Number Publication Date
AR062038A1 true AR062038A1 (es) 2008-08-10

Family

ID=37075006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103275A AR062038A1 (es) 2006-07-24 2007-07-24 Neurotrofinas modificadas post-traduccionalmente

Country Status (11)

Country Link
US (2) US20100055109A1 (es)
EP (2) EP1882697B1 (es)
JP (1) JP5528803B2 (es)
AR (1) AR062038A1 (es)
AT (1) ATE465179T1 (es)
BR (1) BRPI0714545A2 (es)
CA (1) CA2657563A1 (es)
DE (1) DE602006013809D1 (es)
HK (1) HK1116806A1 (es)
UY (1) UY30501A1 (es)
WO (1) WO2008012049A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006013809D1 (de) * 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
WO2012033916A1 (en) * 2010-09-08 2012-03-15 Southern Illinois University Edwardsville Method for treating chronic pain
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
US20180236031A1 (en) * 2017-02-10 2018-08-23 Vivibaba, Inc Compositions and methods for recombinant nerve growth factor
CA3095125A1 (en) * 2018-03-27 2019-10-03 Factor Bioscience Inc. Nucleic acid-based therapeutics

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5994524A (en) 1994-07-13 1999-11-30 Chugai Seiyaku Kabushiki Kaisha Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same
US6068040A (en) 1998-07-24 2000-05-30 Alpine Overhead Doors, Inc. Slat edge retainer for overhead rolling doors
EP1500399A1 (en) * 2003-07-24 2005-01-26 Institut Pasteur Active or passive immunization against proapoptotic neurotrophins for the treatment or prevention of neurodegenerative deseases
DE602006013809D1 (de) * 2006-07-24 2010-06-02 Facultad De Medicina Universid Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden

Also Published As

Publication number Publication date
HK1116806A1 (en) 2009-01-02
UY30501A1 (es) 2009-04-30
US9328163B2 (en) 2016-05-03
JP2010501475A (ja) 2010-01-21
ATE465179T1 (de) 2010-05-15
WO2008012049A1 (en) 2008-01-31
CA2657563A1 (en) 2008-01-31
US20100055109A1 (en) 2010-03-04
DE602006013809D1 (de) 2010-06-02
EP2046823A1 (en) 2009-04-15
US20140178384A1 (en) 2014-06-26
BRPI0714545A2 (pt) 2013-05-14
EP1882697A1 (en) 2008-01-30
EP1882697B1 (en) 2010-04-21
EP2046823B1 (en) 2012-11-21
JP5528803B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
AR062038A1 (es) Neurotrofinas modificadas post-traduccionalmente
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
NI201000033A (es) Amidas heterocíclicas útiles para el tratamiento de cáncer y psoriasis
NI200700296A (es) Imidazoquinolinas como inhibidores de cinasa de lipido
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
CO6382129A2 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o provencion de diabetes
ECSP10010372A (es) Métodos y composiciones que utilizan polipéptidos de fusión de klotho-fgf
GT200600280A (es) Composiciones y metodos para el tratamiento de sintomas relacionados con el ciclo
CR10211A (es) Compuestos de tiazol y métodos de uso
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
UY33206A (es) Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4
AR107579A1 (es) Composiciones y métodos para disminuir la expresión de tau
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
DE602006015387D1 (de) Beta-2 Adrenoceptor Agonisten zur Behandlung von Bindegewebserkrankungen der Haut
JO2581B1 (en) Aryl sulfonomides replaced
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
NZ582930A (en) Tissue kallikrein for the treatment of diseases associated with amyloid protein
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
PA8574701A1 (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen
CO2023018231A2 (es) Restos de administración terapéutica novedosos y usos de estos

Legal Events

Date Code Title Description
FB Suspension of granting procedure